###### Strengths and limitations of this study

-   Our study contains one of the largest cohorts of abstinent smokers followed up for 12 months and thus allows more precise estimates of weight gain than most similar studies.

-   Moreover, the cohort was well phenotyped at baseline and had serial weight measurements, which allowed us to characterise the trajectory of weight gain.

-   The main limitation of our study is that it was based on the data from a routine clinic and not designed to assess the true determinants of weight change (eg, caloric intake, physical activity, resting metabolic rate), and thus we lack data on the true causal factors underlying weight gain.

Introduction {#s1}
============

Postcessation weight gain (PCWG) is a well-known phenomenon[@R1] which occurs in majority of quitters[@R5] and the average weight gain is nearly 5 kg at 1 year postquit.[@R3] However, weight change after cessation varies greatly, with around 16% losing weight while 13% gain more than 10 kg and it is currently unclear what predicts excess weight gain.[@R3] The rate of weight gain is highest in the first 3 months after quitting.[@R3]

The exact mechanisms underlying weight gain are not clearly understood. It has been suggested that the occurrence of PCWG in most quitters is a result of imbalance in which energy input (eg, caloric intake) is in disequilibrium with energy expended (eg, physical activity, resting metabolic rate).[@R1] On the other hand, it remains unclear why this imbalance occurs. One possible explanation is nicotine withdrawal.[@R8] Although nicotine does not have an anorectic function and does not acutely reduce hunger and eating,[@R9] it reduces food consumption and increases basal metabolic rate.[@R8] In animal models, a decreased appetite was caused by binding of nicotine to the β4 subunit of nicotinic acetylcholine receptors in the hypothalamus, which stimulates the melanocortin-4 (MC-4) subunit of pro-opiomelanocortin neurons.[@R10] Increased appetite after smoking cessation is a frequent and long-lasting withdrawal symptom[@R11] and increased self-administration of palatable foods (ie, fatty meals and sweets) has been described after nicotine deprivation.[@R12] Furthermore, smokers display an altered brain response to food in the hypothalamus, which is an area associated with long-term weight change in non-smokers.[@R13] Additionally, delayed gastric emptying of solids has been explored in smokers[@R14] and recent data described accelerated gastric motility after stopping smoking, and this may be involved in the temporary appetite increase.[@R16] The role of gut microbiota modulation after smoking cessation has been introduced recently: profound shifts in the microbial composition and diversity were observed, and these changes seem to be similar to those already reported in obese compared with lean people, suggesting a potential pathogenetic link between weight gain and smoking cessation.[@R17] Finally, the role of hereditary factors in weight changes after smoking cessation was suggested in a study with monozygotic and dizygotic twin quitters.[@R18]

PCWG is important. Fear of weight gain may be an important barrier for quitting smoking[@R20] or may lead to loss of motivation and to relapse.[@R21] In addition, weight gain has adverse consequences increasing cardiometabolic risk.[@R3]

It would be helpful to identify those at high risk of excessive weight gain and intervene before they gain excessively. Risk factors for those at higher risk of PCWG have been intensively studied and identified (eg, higher baseline smoking rate, more severe cigarette dependence, less physical activity and a report of increased appetite on the baseline assessment of withdrawal symptoms,[@R4] baseline weight (smokers who are obese gain most weight on quitting smoking)[@R22]) and others. However, these risk factors only poorly predict PCWG[@R22] and thus cannot be used to identify high-risk smokers before they stop smoking that may benefit from interventions to prevent excessive weight gain. One plausible risk factor is early rapid weight gain; if a person has manifested weight gain already, this may well be the most important risk factor, but there are no data on whether this is the case. It is also plausible that a person who has gained weight rapidly may be motivated to address their weight. Finally, it may be easier for people to engage in weight control once they have passed the initial period of tobacco withdrawal. The main research question of this analysis is whether early large PCWG (ie, the weight gain within 3 months after quitting smoking) predicts overall large PCWG (ie, the total weight gain after 12 months since the quit date). Additionally, we examined other predictors of long-term PCWG and performed the receiver operating characteristic (ROC) analysis to find a cut point in the amount of early PCWG beyond which greater longer-term PCWG is likely to occur.

Materials and methods {#s2}
=====================

Tobacco dependence treatment programme {#s2a}
--------------------------------------

This study population comprises patients treated at the Centre for Tobacco-Dependence in Prague, Czech Republic, between 2005 and 2013. This centre used evidence-based tobacco treatment procedures including pharmacotherapy and psychobehavioural interventions according to Czech and international treatment recommendations and guidelines,[@R23] described on our webpage at <http://www.slzt.cz/intervention-structure>. The multidisciplinary treatment team consisted of nurses and medical doctors who were certified as tobacco treatment specialists by the Mayo Clinic Accredited Tobacco Treatment Specialist Programme (accredited by the Council on Tobacco Treatment Training Programmes), and its equivalent in the Czech Republic under the Society for Treatment of Tobacco Dependence (accredited by the Czech Medical Association). The treatment is individualised and differs in the type of medication used (varenicline; bupropion; nicotine replacement therapy (NRT); the method of NRT including the patch, lozenge, inhaler and gum and/or in combination, if needed), and the number of clinic visits recommended depending on the history, preferences, adherence of patients and the presence of other comorbidities.

The initial visit, which included baseline assessments, was similar for all patients. The degree of tobacco dependence (Fagerström Test of Cigarette Dependence (FTCD)[@R25] and Minnesota Withdrawal Scale (MNWS)[@R27]) were assessed, medical history was collected and a basic physical examination was performed, which included height and weight.

At the second visit, physical dependence and psychosocial tobacco dependence were discussed during the 2-hour clinical intervention. Habits and rituals associated with tobacco use, alternative or surrogate means of resolving problems or avoiding such situations were analysed; and pharmacotherapy was introduced. At the end of the second visit, the patient and tobacco treatment specialist determined the subsequent course of treatment, including pharmacotherapy type and dose. They also planned the target quit date and the date of the first follow-up visit. Medication was prescribed based on the patient's history and choice. The first-line medications used in the clinical practice included varenicline, bupropion and/or nicotine. Whereas varenicline and bupropion were used in standard or reduced dosing, NRT was recommended either as the patch plus method (ie, patch in combination with an oral form of NRT---gum, mouth spray, oral strips, inhaler or lozenge) or in oral form only. Dosing of NRT was adjusted individually according to the presence of nicotine withdrawal symptoms during tobacco treatment. In accordance to Czech and international treatment recommendations and guidelines,[@R23] all drugs were recommended to be used for at least 3 months or longer if needed, according to withdrawal symptoms. The second visit also contained brief weight management recommendations, as described by Fiore and colleagues.[@R23]

Follow-up visits lasted an average of 30 min. The first of these was planned within 1 or 2 weeks of the target quit day, and then about once a month through the third month of treatment. Regular in-person visits occurred at 6 and 12 months postquit date, with a higher frequency if needed. At each visit measurements of body weight, carbon monoxide (CO) in expired air, blood pressure and heart rate were taken. Anyone that failed to attend a planned appointment was contacted by phone and classified as smoking if they did not attend as planned.

Participants {#s2b}
------------

All participants signed a consent form to allow their data to be used in future studies such as this and this study was approved. The cohort consisted of 1050 smokers who underwent tobacco dependence treatment at the Centre for Tobacco-Dependence in Prague, Czech Republic, between 2005 and 2013. Out of 3537 patients treated during above-mentioned period, only 1050 fulfilled the inclusion criteria and were included in this analysis: 12 months of continuous abstinence (according to the Russell Standard Criteria[@R28]) verified by an exhaled CO of less than 6ppm. Those who did not meet the above-mentioned inclusion criteria were excluded from this study.

Patient and public involvement {#s2c}
------------------------------

Patients were not involved in the research question development, setting of outcome measures, study design, recruitment and conduct of this study.

Study measures {#s2d}
--------------

-   Weight: The body weight was measured at each visit using the personal digital scale ETA1775 90000, light clothes, shoes off.

-   Body mass index (BMI): BMI is the ratio of body weight to the body surface calculated using the standard formula of kg/m2.[@R29]

-   Beck Depression Inventory (BDI) score: Depressive symptoms were assessed at the baseline interview using the BDI.[@R30] For analyses, patients were categorised into none or minimal (BDI \<13), mild (BDI 14--19), moderate (BDI 20--28) and severe (BDI \>28) depression.

-   Tobacco dependence (FTCD): Tobacco dependence was measured using the FTCD[@R25] at the baseline. An FTCD score of 5 or greater means severe dependence on tobacco.

-   Number of cigarettes per day: Number of cigarettes smoked per day at the baseline visit (prior to any intervention).

-   Regular smoking initiation age: Age when the smoker started to smoke regularly.

-   Pharmacotherapy used: including bupropion, varenicline, NRT.

-   Withdrawal symptoms: Withdrawal symptoms were assessed using the MNWS[@R27] at each visit for last 24 hours (score 0--4, where 4 means the most severe intensity and 0 means none). For this analysis, we used scores on one item related to noticing appetite and weight increases and the values recorded at baseline and at 3 months.

Data analysis {#s2e}
-------------

A special programme, ELZT (Evidence Léčby Závislosti na Tabáku-Register of Tobacco Dependence Treatment) was developed to collect and summarise data from the Centre for the Treatment of Tobacco Dependence, General University Hospital and 1 st Faculty of Medicine, Charles University.

Data were analysed by the Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science Masaryk University, Brno. Baseline characteristics were summarised using mean±SD and median with quartiles for continuous variables and using absolute and relative frequencies for categorical variables. Body measurement changes from baseline to 1 year were calculated as absolute change and also as percentage change. A one-sample t-test assessed the significance of change in weight against zero (no change). The relation between relative changes in early weight gain and weight gain up to 1-year follow-up period were assessed by Pearson correlation. The aim was to set a threshold of early weight gain (ie, within 3 months of the quit date), which might indicate further weight gain. We assessed this in two different ways: (1) Change in early weight gain/loss was dichotomised at the median and mean weight change from that point forward to 1 year was compared by a two-sample t-test. (2) Then the ROC analyses were used to find cut-offs for definition of limits for risk subgroups. Cut-offs were chosen using the best combination of sensitivity (true-positive rate) and specificity (true-negative rate). We preferred higher sensitivity to specificity. This is because in any future use of the cut-offs will aim to maximise health gain by offering weight control interventions to anyone at high risk.

Analysis of variance and Pearson correlation were used to assess the association between 1-year weight gain and baseline characteristics. A multiple linear regression model followed univariate analyses; all factors were included in the model except for BDI score, which was missing in many patients and, moreover, BDI score was not statistically significantly associated in the univariate analysis. In addition, multiple imputation of missing data of all involved variables was applied; the fully conditional specification method based on an iterative Markov chain Monte Carlo method was chosen because the pattern of missing data was arbitrary (BMI was imputed in two patients; FTCD, number of cigarettes per day and age at smoking initiation were imputed in three patients and BDI was imputed in 162 patients). Full multivariable linear model including BDI score were created on the imputed data. Multivariable models were used to assess the association between early weight gain and subsequent weight gain controlling for other possible factors associated with weight gain (gender, age, BMI, BDI, FTCD, number of cigarettes, age at smoking initiation, physical activity and pharmacotherapy). In addition, we computed association between the withdrawal appetite scoreat 3 months and mean weight gain at 12 months. The sensitivity analysis with those present at both time points (n=566) was performed in order to examine the predictive ability of early weight regain on later weight regain. All tests were done on a significance level α=0.05, analyses were conducted using SAS V.9.4 and IBM SPSS StatisticsV.23.

Results {#s3}
=======

The baseline characteristics of our patients are shown in [table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics (n=1050)\*

  ----------------------------------------------------------------------------------------------------------
  Personal characteristics                                  N (%)†        Mean (±SD)‡ Median (25th; 75th)‡
  --------------------------------------------------------- ------------- ----------------------------------
  Patients stopped smoking with 1-year follow-up (n=3043)   1050 (34.5)   

  Gender (n=1050)                                                         

   Female                                                   511 (48.7)    

   Male                                                     539 (51.3)    

  Age at baseline visit (years) (n=1050)                                  46.2 (±14.4)\
                                                                          45.0 (33.0; 58.0)

   ≤39                                                      421 (40.1)    

   40--49                                                   173 (16.5)    

   50--59                                                   223 (21.2)    

   ≥60                                                      233 (22.2)    

  Weight (kg) (n=1050)                                                    80.0 (±16.8)\
                                                                          78.6 (67.1; 91.8)

   \<60                                                     110 (10.5)    

   60--79                                                   446 (42.5)    

   80--99                                                   358 (34.1)    

   100--119                                                 122 (11.6)    

   ≥120                                                     14 (1.3)      

  BMI (kg/m^2^) (n=1048)                                                  26.4 (±9.3)\
                                                                          25.7 (22.9; 28.8)

   \<20                                                     59 (5.6)      

   20--25                                                   392 (37.4)    

   25--30                                                   400 (38.2)    

   ≥30                                                      197 (18.8)    

  BDI score (n=890)§                                                      8.7 (±7.7)\
                                                                          7.0 (3.0;12.0)

   Minimal depression                                       272 (33.5)    

   Mild depression                                          427 (52.5)    

   Moderate depression                                      94 (11.6)     

   Severe depression                                        20 (2.5)      

  FTCD (n=1046)                                                           5.5 (±2.3)\
                                                                          6.0 (4.0;7.0)

   0--5                                                     527 (50.4)    

   ≥6                                                       519 (49.6)    

  Cigarettes per day (n=1045)                                             22 (±9.6)\
                                                                          20 (20;25)

   1--10                                                    98 (9.4)      

   11--20                                                   585 (56.0)    

   21--30                                                   243 (23.3)    

   ≥31                                                      119 (11.4)    

  Regular smoking initiation age (n=1046)                                 19 (±4.9)\
                                                                          18.0 (16;20)

   ≤18                                                      604 (57.7)    

   ≥19                                                      442 (42.3)    

   Physical activity (n=1050)                                             

   Regularly (more times weekly)                            264 (25.1)    

   Weekly                                                   189 (18.0)    

   Irregularly                                              206 (19.6)    

   Never                                                    391 (37.2)    

  Pharmacotherapy used¶ (n=1050)                                          

   Bupropion                                                89 (8.5)      

   Varenicline                                              672 (64.0)    

   Nicotine replacement therapy                             598 (57.0)    

   Without therapy                                          66 (6.3)      
  ----------------------------------------------------------------------------------------------------------

\*BDI; FTCD.

†Discrete variables are described by number and percentage.

‡Continuous variables are described by mean (±SD) and median with 25--75 percentiles.

§BDI is only available for patients entered in 2007 and thereafter. It was not administered to patients early in the programme (2005--2006).

¶Each patient could have more than one pharmacotherapy.

BDI, Beck Depression Inventory; FTCD, Fagerström Test of Cigarette Dependence.

The sample of 1050 successful abstainers consisted of 511 (48.7%) women and 539 (51.3%) men with the mean age of 46 (±14.4) years. The mean PCWG after 1 year was +4.1% (±5.31%) of the baseline weight. When examined by month, it was 0.79% (±2.03%) at first month, 1.49% (±2.58%) at second month and 2.33% (±3.44%) at third month (p\<0.001 for all above-mentioned changes) (see [table 2](#T2){ref-type="table"}, [figure 1](#F1){ref-type="fig"}).

###### 

Early weight gain/loss in the first 3 months after smoking cessation

                                                N      Mean   SD      Median   Minimum   Maximum
  --------------------------------------------- ------ ------ ------- -------- --------- ---------
  Baseline weight (kg)                          1050   80.0   16.78   78.6     44.3      136.0
  Change (kg) in early weight gain in                                                    
   First month                                  763    0.60   1.58    0.50     −4.50     18.20
   Second month                                 646    1.12   2.04    1.10     −7.60     8.00
   Third month                                  566    1.81   2.72    1.80     −11.00    13.30
   Median PCWG during first 3 months            933    1.05   1.82    1.00     −8.55     8.00
  Relative change (%) in early weight gain in                                            
   First month                                  763    0.79   2.03    0.70     −8.2      19.2
   Second month                                 646    1.49   2.58    1.49     −10.1     10.0
   Third month                                  566    2.33   3.44    2.20     −12.7     26.7
   Median PCWG during first 3 months            933    1.37   2.33    1.28     −10.1     12.8

PCWG, postcessation weight gain.

![Relative change in weight (%) in different time points after smoking cessation (mean, SD).](bmjopen-2018-023987f01){#F1}

Between the baseline visit and 3 months after smoking cessation, early weight gain/loss was significantly correlated with subsequent weight gain at 1 year (p=0.018, correlation coefficient was +0.085), which indicated that early weight gain was only weakly related with subsequent weight gain.

If we dichotomised patients according to median of early weight change (1.28%) into above and below the median, subsequent weight gain recorded in patients with early weight gain above median was not significantly higher compared with those under the median value (see [table 3](#T3){ref-type="table"}).

###### 

Weight gain at 1-year follow-up in subgroups defined using median in the first 3 month periods after quit smoking

  Early weight change in   Group\*   Beyond weight gain (%) up to 1 year follow-up                                       
  ------------------------ --------- ----------------------------------------------- ------ ------ ------ ------- ------ -------
  Three months (median)    ≤1.28%    467                                             3.79   5.23   3.55   −12.5   25.2   
                           \>1.28%   466                                             4.13   5.55   3.81   −13.6   26.6   0.384

\*According to median of early weight change (in %).

Findings from the receiver operating curve analysis are shown in [table 4](#T4){ref-type="table"}.

###### 

ROC analyses of early weight gain for groups of patients defined using limits 5%, 7%, 10% wt gain in 1 year follow-up (n=772)

  Weight gain up to 1 year follow-up   Early weight gain (%) ROC analyses                   
  ------------------------------------ ------------------------------------ ------- ------- -------
  5%                                   N~\>5%~=296                          2.28    0.395   0.716
  7%                                   N~\>7%~=201                          2.35    0.426   0.725
  0.98                                 0.658                                0.440           
  10%                                  N~\>10%~=93                          2.86    0.344   0.794

ROC, receiver operating characteristic.

Early weight change during the first 3 months after stopping smoking did not strongly predict subsequent weight gain and it had a low sensitivity. Forty three per cent of patients (n=453) gained more than 7% of their baseline weight by 12 months. A receiver operating curve analysis showed that patients gaining more than 0.98% of their baseline weight during the first 3 months had a sensitivity of 66% and specificity of 44% for gaining 7% or more weight beyond by 12 months. The waterfall plot in [figure 2](#F2){ref-type="fig"} shows that one-third of people who gained less than 0.98% during the first 3 months further gained more than 7% at 1 year, but more than half of those who gained more than 0.98% at this time did not gain morethan 7%.

![Waterfall plot for prediction of subsequent \>7% weight gain up to 1 year FU by early weight change (Each patient is represented by one horizontal line). Patients with \<0.98% weight gain at third month are on the left side; patients with ≥0.98% weight gain on the right side. Grey lines depict correctly predicted patients, that is, positive (≥0.98% early weight gain and \>7% subsequent weight gain up to 1 year; in upper part of plot) and negative (\<0.98% early weight gain and ≤7% subsequent weight gain, in lower part of plot). Black lines depict wrongly predicted patients, that is, false positive (≥0.98% early weight gain but ≤7% subsequent weight gain) and false negative (\<0.98% early weight gain but \>7% subsequent weight gain).](bmjopen-2018-023987f02){#F2}

There was no evidence that participants' appetite ratings at baseline, before quitting, was associated with weight gain at 12 months. However, there was a graded association between appetite ratings at 3 months and weight gain at 12 months ([figure 3](#F3){ref-type="fig"}).

![Average weight gain after 1 year based on patients' reported intensity of withdrawal symptom 'increased appetite, hungry, weight gain' at 3-month visit; whiskers denote 95% CI.](bmjopen-2018-023987f03){#F3}

Multivariate linear regression on imputed data (see [table 5](#T5){ref-type="table"}) showed that significant factors for prediction of higher PCWG after 1 year were lower baseline BMI (B=−0.20; 95% CI −0.29 to −0.11, p\<0.001), being a woman (B=0.78; 0.02 to 1.54, p=0.045), while using NRT was associated with lower weight gain (B=−1.07; −1.88 to −0.26, p=0.01). The mean duration of use of oral forms of NRT was 4.43 months (median 2.88 months) and of nicotine patches 2.72 months (median 2.2 months). The length of pharmacotherapy use was similar for all first-line medications (ie, varenicline, bupropion and NRT).

###### 

Multiple linear model for relative change in weight 1 year after smoking cessation

  Personal characteristics                    Multiple model (n=765)     Model with multiple imputation (n=772)                               
  ------------------------------------------- -------------------------- ---------------------------------------- --------------------------- ---------
  Weight change in third month (%)            0.134 (−0.037 to 0.304)    0.124                                    0.141 (−0.027 to 0.31)      0.101
  Female                                      0.804 (0.039 to 1.57)      0.039                                    0.781 (0.018 to 1.544)      0.045
  Age at baseline visit (years)               −0.005 (−0.034 to 0.024)   0.736                                    −0.006 (−0.034 to 0.023)    0.682
  BMI (kg/m^2^)                               −0.209 (−0.3 to −0.118)    0.000                                    −0.202 (−0.292 to −0.111)   \<0.001
  BDI score                                                                                                       0.021 (-0.037 to 0.078)     0.467
  FTCD score                                  0.004 (−0.211 to 0.218)    0.974                                    0 (−0.214 to 0.214)         1.000
  Cigarettes per day                          0.033 (−0.018 to 0.084)    0.207                                    0.03 (−0.021 to 0.081)      0.243
  Age at regular smoking initiation (years)   0.05 (−0.046 to0.145)      0.307                                    0.045 (−0.05 to 0.14)       0.356
  Bupropion\*                                 0.011 (−1.337 to 1.359)    0.987                                    −0.049 (−1.406 to 1.309)    0.944
  Varenicline\*                               −0.384 (−1.267 to 0.5)     0.395                                    −0.349 (−1.225 to 0.527)    0.435
  Nicotine replacement therapy\*              \`                         0.010                                    −1.068 (−1.879 to −0.257)   0.010
  Physical activity                                                                                                                           
   Regularly (more times weekly)              −1.015 (−2.072 to 0.042)   0.060                                    −0.957 (−2.01 to 0.095)     0.075
   Weekly                                     −0.137 (−1.185 to 0.911)   0.798                                    −0.1 (−1.146 to 0.946)      0.851
   Irregularly                                0.402 (−0.657 to 1.462)    0.457                                    0.466 (−0.586 to 1.519)     0.385
   Never                                      ref.                                                                ref.                        
   Intercept                                  8.411 (4.993 to 11.828)    \<0.001                                  8.208 (4.795 to 11.621)     \<0.001

\*Using of specified pharmacotherapy (in monotherapy or in combination with other therapy).

BDI, Beck Depression Inventory; BMI, body mass index; FTCD, Fagerström Test of Cigarette Dependence.

The sensitivity analysis performed with those present at both time points (n=566) found the same factors significant in the main multivariate analysis as those from the whole sample of abstainers who missed any visit.

Early weight gain was not associated with additional weight gain thereafter when assessed at 1 year (B=0.14, 95% CI −0.03--0.31, p=0.101).

Discussion {#s4}
==========

There was not a statistically significant relationship between early weight gain and later weight gain. As a result, early weight gain above the median had a moderate sensitivity (66%) and somewhat low specificity (44%) for gaining at least 7% of baseline weight by 12 months. In multivariable analysis, having a lower BMI at baseline, starting smoking in adulthood and using either no medication or medication other than NRT were independently associated with greater weight gain at 1 year. In addition, postcessation appetite ratings were associated with greater weight gain. The relationship between early and later weight gain seems to be positive, but the discrepant findings from different analyses indicate that their relationship is weak.

We found that higher appetite ratings at 3 months were associated with greater weight gain at a year, but there was no association between appetite ratings at baseline, prior to quitting, and PCWG. This latter finding contrasts with those of Kmetova *et al*,[@R4] where ratings of appetite prior to a quit attempt were associated with PCWG. To our knowledge, our finding that withdrawal symptoms of appetite intensity after smoking cessation have been associated with weight gain is in line with previously published studies.[@R31] That 3 months appetite ratings were a predictor suggests that this effect is long-lived, which consonant with continued weight gain over continued smoking observed in populations is observed even beyond the first year.[@R22]

This study has several strengths. It is one of the largest cohorts of abstinent smokers followed up and thus allows more precise estimates of weight gain than most similar studies. Moreover, the cohort was well phenotyped at baseline and had serial weight measurements, which allowed us to characterise the trajectory of weight gain, which has previously been possible only in repeat cross-sectional samples.[@R3] Perhaps, participants who were gaining weight rapidly noticed this and took actions to limit weight gain, which may explain why there was only a weak association between early and later weight gain. The most likely variables to be associated with greater or lower weight gain are likely to be the actions participants take to limit weight gain by limiting energy intake and maximising expenditure and the strength of drive to eat that participants experience after quitting smoking. There was evidence that the strength of drive to eat may explain greater weight gain, where postcessation ratings were associated with higher weight gain.

On the other hand, there are some limitations of our work. This study was based on the data from a routine clinic and not designed to assess the true determinants of weight change, which must relate to change in energy balance, and which are burdensome for participants to measure properly, and thus we lack data on the true causal factors underlying weight gain. No studies, to our knowledge, have ever tracked these factors through the first year of abstinence. This limitation particularly affects the study of factors associated with greater weight gain, which must be confined to indirect but easy to measure factors.

The extent of weight gain in this cohort was similar to that observed in previous studies and documented in a meta-analysis of such studies.[@R3] However, as in the meta-analysis of previous studies, we found a large variation between individuals in the extent of weight gain. This implies that the mean weight gain is a poor predictor of what any individual might gain, so we need to identify better predictors if we are to offer targeted interventions to prevent excess weight gain. Unfortunately, even early manifest weight gain is a poor predictor of excess weight gain and our other predictors also accounted for only a matter of hundreds of grams difference between those with and without a particular risk factor, whereas there was a 5 kg difference in weight between a person in the 25th and 75th centile of the weight gain distribution. Nevertheless, there were some more potent predictors. Chief among these were BMI at baseline. The higher the BMI, the lower the weight gain. Other studies have reported both positive and negative associations with BMI and, overall, it seems that baseline BMI may not be a strong predictor of weight gain.[@R22] Starting smoking later in life emerged as an unexpected predictor of higher weight gain, but a previous study has suggested that those who initiate smoking earlier may have higher weight gain.[@R22] Third, using NRT was associated with lower weight gain. A meta-analysis of randomised trials suggests that, of all the licensed medications, bupropion may have the largest effect on weight gain,[@R34] so this result may appear unexpected. However, people do not use varenicline or bupropion for more than a few months when stopping smoking, and there is no strong evidence that bupropion reduces weight gain in the long-term.[@R34] Instead, the most likely explanation is that a sizeable proportion of people who seek treatment for tobacco dependence and who quit with NRT use it for at least a year and this is associated with and probably causes lower weight gain.[@R35]

These data have important implications for the treatment of tobacco dependence. We have conducted trials of interventions to limit weight gain where the interventions to do so have started concurrently with the attempt to achieve abstinence.[@R36] These interventions have been proven unpopular with people trying to stop smoking and the trials have failed to recruit. A promising avenue that may increase participants' desire to address weight gain may have been to wait until excess weight gain had been manifest and then intervene with a weight control programme. However, this study shows that, while early excessive weight gain does predict subsequent higher weight gain, it does so only weakly; many people who will not gain excessively would need to be treated and some people who will gain excessive weight will not be offered treatment. It may therefore be necessary to find ways to reframe the offer of weight control so that it is more attractive to people attempting to stop smoking, which may be helped if we can identify those at the greatest risk of health-damaging weight gain.

Conclusions {#s5}
===========

In conclusion, in people who stopped smoking for a year, excess weight gain in the first few months of abstinence is a poor predictor of later and excessive gain and there appear to be no other strong predictors of excessive weight gain that are measured in a routine smoking cessation clinic.
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